Sunday, November 22, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· November 27, 2025

CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi

View original at globenewswire.com
CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi Dublin, Nov…
Opening lines of the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • CD38 is an attractive target for antibody therapy because it is highly expressed on malignant plasma cells

    100% confidence
  • CD38 is a clinically validated and commercially very successful target

    100% confidence
  • Multiple Myeloma represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors

    100% confidence
  • The patent holder of Darzalex expects that royalties from sales of DARZALEX will begin to decline materially in 2029 following expiration of U.S. patent rights on daratumumab

    95% confidence

Cited in these Via News reports

CD38-Targeted Immunotherapies Pipeline and Competitive Intelligence Report 2025: Darzalex Became the Number 4 Blockbuster Biologic, Just Behind Keytruda, Dupixent and Skyrizi: Source | Via News | vianews.market